Please Wait.....
Report
Liver Fibrosis Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-12 I 180 Pages I EMR Inc.
Liver Fibrosis Market Report and Forecast 2024-2032
Liver Fibrosis Market Outlook
The liver fibrosis market size was valued at USD 2.32 billion in 2023, driven by the increasing trend towards non-invasive diagnostic methods across the major markets. The market size is anticipated to grow at a CAGR of 7.7% during the forecast period of 2024-2032 to achieve a value of USD 4.52 billion by 2032.
Liver Fibrosis: Introduction
Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, that occurs in most types of chronic liver diseases. It's the liver's response to injury or inflammation, where normal liver tissue gradually gets replaced by scar tissue. This scarring process can eventually disrupt liver function, leading to cirrhosis if untreated. Factors like chronic hepatitis, alcohol abuse, and fatty liver disease contribute to fibrosis. Early stages are often reversible with treatment and lifestyle changes.
Key Trends in the Liver Fibrosis Market
There's a growing trend towards non-invasive diagnostic methods, such as elastography and biomarker tests, to assess liver fibrosis. These methods are favored for their ability to reduce patient discomfort and the risks associated with liver biopsies, while allowing for more frequent monitoring of liver health.
Personalized medicine is becoming more prominent, with treatments being tailored based on the individual's genetic makeup, stage of fibrosis, and underlying cause. This approach aims to improve treatment efficacy and patient outcomes.
Research and development of antifibrotic drugs are intensifying, with several compounds in various stages of clinical trials. These therapies aim to halt the progression of fibrosis, promote fibrosis regression, and improve liver function.
There's an increasing focus on combination therapies that target multiple pathways involved in the progression of liver fibrosis. This approach aims to enhance treatment effectiveness compared to monotherapy options.
Public health initiatives promoting liver health, and awareness about conditions leading to liver fibrosis, like hepatitis, alcohol abuse, and fatty liver disease, are on the rise. Preventive measures, including vaccination, lifestyle modifications, and regular screenings, are emphasized to reduce the incidence of liver fibrosis.
Digital health solutions, including mobile apps and telemedicine, are being increasingly used for patient monitoring and management. These technologies support remote patient monitoring, medication adherence, and patient education, contributing to better disease management and patient outcomes.
Liver Fibrosis Market Segmentation
Market Breakup by Condition
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
Market Breakup by Treatment
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- ACE Inhibitors
- Hepatotropic Drug
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Stores and Pharmacy
- Online Providers
Market Breakup by End User
- Hospitals
- Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
Liver Fibrosis Market Overview
In North America, the liver fibrosis market is advanced, characterized by significant research in liver diseases and a strong emphasis on early diagnosis and treatment. The region has a high prevalence of liver-related conditions due to factors like obesity and hepatitis C. This drives demand for non-invasive diagnostic tests and innovative treatment options. The U.S. leads in drug development and the adoption of novel therapies, supported by a well-established healthcare infrastructure and proactive patient advocacy groups.
Europe's market is marked by comprehensive healthcare systems and a focus on healthcare innovation. The region benefits from concerted efforts in research, particularly in understanding liver diseases and developing antifibrotic therapies. Public health initiatives aimed at reducing alcohol consumption and managing metabolic syndrome factors contribute to the market dynamics. The EU's regulatory framework supports the development and fast-track approval of advanced therapies, ensuring access to cutting-edge treatment for liver fibrosis.
Japan's market for liver fibrosis is influenced by a high standard of healthcare and a strong focus on research and technological innovation. The country has a notable prevalence of liver diseases, particularly hepatitis B and C, driving the demand for effective treatment options. Japan's rapid adoption of non-invasive diagnostic techniques and advanced therapies, coupled with substantial government investment in healthcare, makes it a leading market in the Asia-Pacific region for liver fibrosis treatment and management.
Liver Fibrosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- F. Hoffmann-La Roche
- Mylan N.V.
- Sanofi
- GlaxoSmithKline plc
- AstraZeneca
- Johnson & Johnson
- Merck & Co.
- Bristol-Myers Squibb
- Vertex Pharmaceuticals
- FibroGen, Inc.
- Pharmaxis
- Dicerna Pharmaceuticals, Inc.
- Dynavax Technologies
- GlaxoSmithKline plc
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Liver Fibrosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Success Rate
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Liver Fibrosis Epidemiology Analysis - 7MM
6.1 7MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.1 Germany Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.2 France Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.3 Italy Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.4 Spain Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Liver Fibrosis Epidemiology Forecast (2017-2032)
6.4 Japan Liver Fibrosis Epidemiology Forecast (2017-2032)
7 Liver Fibrosis Market Overview - 7MM
7.1 Liver Fibrosis Market Historical Value (2017-2023)
7.2 Liver Fibrosis Market Forecast Value (2024-2032))
8 Liver Fibrosis Market Landscape-7MM
8.1 Liver Fibrosis Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Liver Fibrosis Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Liver Fibrosis Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Liver Fibrosis Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.3 Porter's Five Forces Model
11.4 Key Demand Indicators
11.5 Key Price Indicators
11.6 Industry Events, Initiatives, and Trends
11.7 Value Chain Analysis
12 Liver Fibrosis Market Segmentation -7MM
12.1 Liver Fibrosis Market by Condition
12.1.1 Market Overview
12.1.2 Chronic Liver Diseases
12.1.3 Hepatitis C
12.1.4 Nonalcoholic Steatohepatitis
12.2 Liver Fibrosis Market by Treatment
12.2.1 Market Overview
12.2.2 Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
12.2.3 ACE Inhibitors
12.2.4 Hepatotropic Drug
12.2.5 Others
12.3 Liver Fibrosis Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital pharmacies
12.3.3 Retail Stores and Pharmacy
12.3.4 Online Providers
12.4 Liver Fibrosis Market by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Clinics
12.4.4 Others
12.5 Liver Fibrosis Market by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
13 United States Liver Fibrosis Market
13.1 Liver Fibrosis Market Historical Value (2017-2023)
13.2 Liver Fibrosis Market Forecast Value (2024-2032)
13.2.1 Liver Fibrosis Market by Disease Type
13.2.2 Liver Fibrosis Market by Treatment Type
14 EU-4 and United Kingdom Liver Fibrosis Market
14.1 Liver Fibrosis Market Historical Value (2017-2023)
14.2 Liver Fibrosis Market Forecast Value (2024-2032)
14.3 Germany Liver Fibrosis Market Overview
14.3.1 Liver Fibrosis Market by Disease Type
14.3.2 Liver Fibrosis Market by Treatment Type
14.4 France Liver Fibrosis Market Overview
14.4.1 Liver Fibrosis Market by Disease Type
14.4.2 Liver Fibrosis Market by Treatment Type
14.5 Italy Liver Fibrosis Market Overview
14.5.1 Liver Fibrosis Market by Disease Type
14.5.2 Liver Fibrosis Market by Treatment Type
14.6 Spain Liver Fibrosis Market Overview
14.6.1 Liver Fibrosis Market by Disease Type
14.6.2 Liver Fibrosis Market by Treatment Type
14.7 United Kingdom Liver Fibrosis Market Overview
14.7.1 Liver Fibrosis Market by Disease Type
14.7.2 Liver Fibrosis Market by Treatment Type
15 Japan Liver Fibrosis Market
15.1 Liver Fibrosis Market Historical Value (2017-2023)
15.2 Liver Fibrosis Market Forecast Value (2024-2032)
15.2.1 Liver Fibrosis Market by Disease Type
15.2.2 Liver Fibrosis Market by Treatment Type
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mylan N.V.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Sanofi
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline plc
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 AstraZeneca
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson & Johnson
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bristol-Myers Squibb
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Vertex Pharmaceuticals
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 FibroGen, Inc.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Pharmaxis
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Dicerna Pharmaceuticals, Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Dynavax Technologies
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 GlaxoSmithKline plc
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Liver Fibrosis Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security